Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02240706
Recruitment Status : Recruiting
First Posted : September 16, 2014
Last Update Posted : May 15, 2019
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
Phase I: To investigate maximum tolerated dose (MTD), safety and tolerability, pharmacokinetics, exploratory biomarker and efficacy of BI 836858 monotherapy in patients with low or intermediate-1 risk myelodysplastic syndromes (MDS) with symptomatic anemia. Phase II: To investigate safety and efficacy of BI 836858 plus Best Supportive Care compared to Best Supportive Care alone in low or intermediate-1 risk MDS patients with symptomatic anemia.

Condition or disease Intervention/treatment Phase
Myelodysplastic Syndromes Procedure: Best Supportive Care Drug: BI 836858 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II, Multicentre, Open-label, Dose Escalation and Randomized Trial of BI 836858 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes
Actual Study Start Date : January 22, 2015
Estimated Primary Completion Date : December 17, 2021
Estimated Study Completion Date : December 17, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Arm B
Best Supportive Care Alone
Procedure: Best Supportive Care
At Discretion of the Investigator (Transfusions)

Experimental: Arm A
BI 836858 plus Best Supportive Care
Procedure: Best Supportive Care
At Discretion of the Investigator (Transfusions)

Drug: BI 836858
Monotherapy with BI 836858




Primary Outcome Measures :
  1. Phase I: Maximum Tolerated Dose [ Time Frame: up to 4 weeks ]
  2. Phase II: Number of Patients with red blood cell (RBC) transfusions [ Time Frame: up to 6 months ]
  3. Phase I: Occurrence of Dose Limiting Toxicity (DLT) [ Time Frame: up to 4 weeks ]

Secondary Outcome Measures :
  1. Number of patients with neutrophil response (HI-N) [ Time Frame: up to 6 months ]
  2. Time to HI-E response [ Time Frame: up to 6 months ]
  3. Duration of Response [ Time Frame: up to 18 months ]
  4. Overall objective Response (OR) [Complete Remission (CR), Partial Remission (PR), and Hematologic Improvement (HI)] [ Time Frame: up to 18 months ]
  5. Phase I: Number of Patients with red blood cell (RBC) transfusions [ Time Frame: up to 6 months ]
  6. Number of patients with erythroid response (HI-E) [ Time Frame: up to 6 months ]
  7. Number of patients with platelet response (HI-P) [ Time Frame: up to 6 months ]
  8. Mean hemoglobin increase ≥ 1.5 g/dL [ Time Frame: up to 48 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Documented diagnosis of Myelodysplastic Syndromes (MDS) according to World Health Organization (WHO) criteria that meets International Prognostic Scoring System (IPSS) classification of low or intermediate-1 risk disease at screening as determined by microscopic and standard cytogenetic analyses of the bone marrow and peripheral complete blood count (CBC).

    • Phase I dose escalation: patients who experienced Erythropoiesis-Stimulating Agents (ESA) treatment failure or do not qualify (serum erythropoietin level > 500 U) for ESA treatment, and are refractory to or not amenable or eligible for established MDS therapy (Hypomethylating Agents (HMA), lenalidomide)
    • Phase I expansion:

      • Expansion cohort 1 ("pre-treated"): patients who experienced ESA treatment failure or do not qualify (serum erythropoietin level > 500 U) for ESA treatment and are refractory to established MDS therapy (HMA and /or lenalidomide)
      • Expansion cohort 2 ("untreated"): patients who experienced ESA treatment failure or do not qualify (serum erythropoietin level > 500 U) for ESA treatment and who have not received prior HMA and/or lenalidomide (because not amenable or eligible for these treatments).
    • Phase II: patients who experienced ESA treatment failure or do not qualify (serum erythropoietin level > 500 U) for ESA treatment. For definition of further details of the phase II patients to be included the protocol will be amended based on Phase I results
  • Patient is non-responsive to, refractory to, or intolerant of ESAs, or ESAs are contraindicated or unavailable, or a documented serum erythropoietin level of > 500 U/L.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status <=2.
  • Age >= 18 years.
  • Written informed consent which is consistent with International Conference on Harmonization - Good Clinical Practice (ICH-GCP) guidelines and local legislation.

Exclusion criteria:

  • Patient with IPSS category of Int-2 or high-risk MDS.
  • Phase II only: Patients with a deletion 5q cytogenetic abnormality.
  • Treatment within 28 days prior to Cycle 1 Day 1 with: i) long acting erythropoiesis stimulating agents, ii) long acting Granulocyte colony-stimulating factor (G-CSF), iii) granulocyte- macrophage colony stimulating factor (GM-CSF), iv) 5-aza, lenalidomide or decitabine, or v) iron chelation and within 14 days prior to Cycle 1 Day 1 with short acting erythropoiesis stimulating agents and short acting G-CSF.
  • Patient previously received allogeneic bone marrow or stem cell transplantation.
  • Second malignancy currently requiring active therapy (except for hormonal/antihormonal treatment, e.g. in prostate or breast cancer).
  • Aspartate amino transferase (AST) or alanine amino transferase (ALT) > 2.5 times the upper limit of normal (ULN).
  • Bilirubin >1.5 mg/dL, except for Gilbert's Syndrome or hemolysis.
  • Serum creatinine >2.0 mg/dL.
  • Known human immunodeficiency virus (HIV) infection and/or active hepatitis B infection (defined as presence of Hep B DNA), active hepatitis C infection (defined as presence of Hep C RNA).
  • Presence of concomitant intercurrent illness, or any condition which in the opinion of the Investigator, would compromise safe participation in the study, e.g. active severe infection, unstable angina pectoris, new onset of exacerbation of a cardiac arrhythmia.
  • Psychiatric illness or social situation which in the opinion of the Investigator would limit compliance with trial requirements.
  • Patient receiving concomitant therapy, which in the opinion of the Investigator is considered relevant for the evaluation of the efficacy or safety of the trial drug.
  • Female patients of childbearing potential who are sexually active and unwilling to use a medically acceptable method of contraception during the trial and for 6 months after the last administration of BI 836858, i.e. combination of two forms of effective contraception (defined as hormonal contraception, intrauterine device, transdermal patch, implantable or injectable contraceptive, bilateral tubal ligation etc.).

Women of childbearing potential are defined as females who:

  • Have experienced menarche and
  • Are not postmenopausal (12 months with no menses without an alternative medical cause) and
  • Are not permanently sterilized (e.g. hysterectomy, bilateral oophorectomy or bilateral salpingectomy

    • Male patients with partners of childbearing potential who are unwilling to use condoms in combination with a second effective method of contraception (defined as hormonal contraception, intrauterine device, condom with spermicide, etc.) during the trial and for 6 months after the last administration of BI 836858.
    • Pregnant or nursing female patients.
    • Treatment with another investigational agent under the following conditions:
  • Within two weeks (4 weeks for biologics) of first administration of BI 836858, or if the half-life of the previous product is known, within 5 times the half-life, whichever is longer.
  • Patient has persistent toxicities from prior MDS therapies which are determined to be relevant by the Investigator.
  • Concomitant treatment with another investigational agent while participating this trial.

    • Chronic use, as defined by > 2 weeks of a corticosteroid agent that is >= 20 mg/day of prednisone or its equivalent, within 4 weeks prior to first administration of BI 836858.
    • Treatment with an immunomodulatory agent within 4 weeks prior to first administration of BI 836858.
    • Patient received prior treatment with a CD33 antibody.
    • In the opinion of the Investigator patient is unable or unwilling to comply with the protocol.
    • Further exclusion criteria apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02240706


Contacts
Layout table for location contacts
Contact: Boehringer Ingelheim Call Center 1-800-243-0127 clintriage.rdg@boehringer-ingelheim.com

Locations
Layout table for location information
United States, Connecticut
Yale University School of Medicine Recruiting
New Haven, Connecticut, United States, 06510
United States, Florida
Mayo Clinic Cancer Center Recruiting
Jacksonville, Florida, United States, 32224
H. Lee Moffitt Cancer Center and Research Institute Recruiting
Tampa, Florida, United States, 33612
United States, Ohio
Cleveland Clinic Recruiting
Cleveland, Ohio, United States, 44195
Germany
Universitätsklinikum Düsseldorf Recruiting
Düsseldorf, Germany, 40225
Sponsors and Collaborators
Boehringer Ingelheim
Investigators
Layout table for investigator information
Study Chair: Boehringer Ingelheim Boehringer Ingelheim

Layout table for additonal information
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT02240706     History of Changes
Other Study ID Numbers: 1315.7
2018-002177-21 ( EudraCT Number )
First Posted: September 16, 2014    Key Record Dates
Last Update Posted: May 15, 2019
Last Verified: May 2019

Additional relevant MeSH terms:
Layout table for MeSH terms
Syndrome
Myelodysplastic Syndromes
Preleukemia
Disease
Pathologic Processes
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Neoplasms